1. Home
  2. DMAC vs GTN Comparison

DMAC vs GTN Comparison

Compare DMAC & GTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

N/A

Current Price

$9.04

Market Cap

501.0M

Sector

Health Care

ML Signal

N/A

GTN

Gray Television Inc.

N/A

Current Price

$5.95

Market Cap

432.5M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
DMAC
GTN
Founded
2000
1897
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
501.0M
432.5M
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
DMAC
GTN
Price
$9.04
$5.95
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
★ $15.50
$6.60
AVG Volume (30 Days)
198.3K
★ 1.2M
Earning Date
11-12-2026
11-06-2026
Dividend Yield
N/A
★ 5.51%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.54
Revenue
$500,000.00
★ $3,095,000,000.00
Revenue This Year
N/A
$19.46
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$5.25
$3.55
52 Week High
$11.00
$6.44

Technical Indicators

Market Signals
Indicator
DMAC
GTN
Relative Strength Index (RSI) 49.91 76.62
Support Level $5.86 $4.32
Resistance Level $11.00 $5.97
Average True Range (ATR) 0.76 0.30
MACD -0.09 0.15
Stochastic Oscillator 29.41 90.31

Price Performance

Historical Comparison
DMAC
GTN

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About GTN Gray Television Inc.

Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.

Share on Social Networks: